CytRx Corporation (CYTR) Completes Acquisition of INNOVIVE Pharmaceuticals
9/22/2008 9:05:15 AM
More...
|
CytRx Corporation (CYTR) Signs Definitive Agreement to Acquire INNOVIVE Pharmaceuticals
6/9/2008 6:27:01 AM
More...
|
INNOVIVE Pharmaceuticals Presents Phase I Data on INNO-406 for Treatment of Gleevec-Resistant or Intolerant Chronic Myelogenous Leukemia at American Society of Hematology
12/10/2007 11:35:43 AM
More...
|
INNOVIVE Pharmaceuticals Presents Preliminary Data at American Society of Hematology Showing INNO-305 Elicits Immune Response in Patients with Myeloid and Thoracic Neoplasms
12/9/2007 11:55:41 PM
More...
|
Data from INNOVIVE Pharmaceuticals' Oncology Drug Programs to be Presented at the American Society of Hematology 49th Annual Meeting
12/5/2007 12:06:52 PM
More...
|
INNOVIVE Pharmaceuticals Initiates Pivotal Phase II Clinical Trial with Tamibarotene
11/15/2007 9:07:35 AM
More...
|
INNOVIVE Pharmaceuticals to Present at the Paramount BioSciences Annual Healthcare Conference
10/19/2007 12:45:23 PM
More...
|
INNOVIVE Pharmaceuticals Announces Receipt of FDA Orphan Drug Designation for Tamibarotene for the Treatment of Acute Promyelocytic Leukemia
10/15/2007 11:28:16 AM
More...
|
INNOVIVE Pharmaceuticals to Present at the Merriman Curhan Ford Investor Summit
9/11/2007 11:48:51 AM
More...
|
INNOVIVE Pharmaceuticals Acquires Exclusive Rights to Develop and Commercialize Tamibarotene in Europe
9/10/2007 11:49:51 AM
More...
|
|